Filing Flows › Comparisons › INO vs RGBP
Inovio Pharmaceuticals vs Regen BioPharma: INO and RGBP compared
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $59K for Regen BioPharma (Q3 FY26).
Where the money goes: INO and RGBP
Inovio Pharmaceuticals (INO) · Q1 2025
Inovio Pharmaceuticals, Q1 2025: revenue $65K, net loss $19.7M, operating cash flow −$26.9M. The chart follows the revenue to costs, profit and cash.
Regen BioPharma (RGBP) · Q3 FY26
Regen BioPharma, Q3 FY26: revenue $59K (0% year over year), operating margin 41.5%, net loss $638K, operating cash flow −$24K. The chart follows the revenue to costs, profit and cash.
| Inovio Pharmaceuticals (INO) | Regen BioPharma (RGBP) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q3 FY26 |
| Revenue | $65K | $59K |
| Revenue growth, Y/Y | — | 0% |
| Operating margin | n/m | 41.5% |
| Net earnings | −$19.7M | −$638K |
| Operating cash flow | −$26.9M | −$24K |
Questions
Which is bigger, Inovio Pharmaceuticals or Regen BioPharma?
Inovio Pharmaceuticals is the larger company: $65K of revenue in its latest quarter (Q1 2025) against $59K for Regen BioPharma (Q3 FY26).
More: Inovio Pharmaceuticals earnings · how Inovio Pharmaceuticals makes money · Regen BioPharma earnings · how Regen BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2025; 10-Q filed Aug 17, 2026). Fiscal quarters can end on different dates. Not investment advice.